Wall Street analysts weighed in on 3D printer maker 3D Systems Corporation (NYSE:DDD) and drug maker Flex Pharma Inc (NASDAQ:FLKS), while both stocks are among the top performers today. Let’s take a look and see what the analysts have to say about DDD and FLKS.
3D Systems Corporation
3D Systems shares are up nearly 28% after the company reported fourth-quarter results, posting earnings per share of $0.19 that handily beat consensus’ expectations. In reaction, Canaccord analyst Robert Burleson raised his price target for the stock to $13 (from $9.00), while keeping his rating at Hold.
Burleson noted, “While we laud cost-cutting efforts by interim management, a return to organic growth may prove difficult in 2016. Effects of year-end budget flush, pent-up capex, and resumption of some demand following quality issues may have boosted top-line results in Q4. It is prudent to assume that results don’t represent the run-rate of normal business and the near term could remain choppy for the top line. We are increasing our price target based on the view that cost-cutting efforts set a higher floor for the stock, and reiterate our Hold rating until we can see signs of sustainable demand improvement.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Robert Burleson has a total average return of 0.3% and a 45% success rate. Burleson has a -11% average return when recommending DDD, and is ranked #1829 out of 3724 analysts.
Flex Pharma Inc
Flex Pharma shares jumped 32% today thanks to positive data from GW Pharmaceuticals’s (NASDAQ:GWPH) Epidiolex, which supports Flex’s emerging science.
Piper Jaffray analyst Joshua Schimmer was the first to commented, “This morning GWPH reported positive Phase 3 results from Epidiolex in Dravet Syndrome which in our view provides a positive readthrough for FLKS given what we hypothesize is a similar mechanism of action. Both drugs potentially act through inhibitory neuronal signaling via TRP receptors enervating the esophagus and stomach, analogous to vagal nerve stimulation in Epilepsy. Though this MOA is not universally accepted by everyone, we believe the emerging science and results from FLKS and GWPH are beginning to validate this mechanism and broader science.”
Schimmer reiterated an Overweight rating on Flex Pharma shares, with a price target of $25, which implies an upside of 147% from current levels.
According to TipRanks.com, Schimmer has a total average return of -22.5% and a 19% success rate. Schimmer has a -41.1% average return when recommending FLKS, and is ranked #3723 out of 3795 analysts.